PeproTech VEGF-165 Monoclonal Antibody, PeproTech®

Description

AA Sequence of recombinant protein: APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR. Preparation: Produced in BALB/c mice immunized with highly pure Recombinant Human VEGF 165. Anti-Human VEGF 165-specific antibody was purified from cell culture by Protein A affinity chromatography. Sandwich ELISA: Assuming 100 μL/well, a concentration of 2.0-4.0 μg/mL of this antibody will detect at least 100 pg/mL of Recombinant Human VEGF 165 when used with PeproTech Biotinylated Antigen Affinity Purified Anti-Human VEGF 165 (500-P10BT) as the detection antibody at a concentration of approximately 0.25- 1.0 μg/mL. Western Blot: To detect Human VEGF 165 by Western Blot analysis this antibody can be used at a concentration of 0.25-0.50 μg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human VEGF 165 is 0.25-0.50 ng/lane, under non-reducing conditions.

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.